Letter | Published:

Depression: a new animal model sensitive to antidepressant treatments

Naturevolume 266pages730732 (1977) | Download Citation

Subjects

Abstract

A MAJOR problem in the search for new antidepressant drugs is the lack of animal models which both resemble depressive illness and are selectively sensitive to clinically effective antidepressant treatments. We have been working on a new behavioural model in the rat which attempts to meet these two requirements. The method is based on the observation that a rat, when forced to swim in a situation from which there is no escape, will, after an initial period of vigorous activity, eventually cease to move altogether making only those movements necessary to keep its head above water. We think that this characteristic and readily identifiable behavioural immobility indicates a state of despair in which the rat has learned that escape is impossible and resigns itself to the experimental conditions. This hypothesis receives support from results presented below which indicate that immobility is reduced by different treatments known to be therapeutic in depression including three drugs, iprindole, mianserin and viloxazine which although clinically active1–3 show little or no ‘antidepressant’ activity in the usual animal tests4–6.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Ayd, F. J. Dis. Nerv. Syst. 30, 818–824 (1969).

  2. 2

    Itil, T. M., Hsu, W. & Polvan, N. Curr. Ther. Res. clin. Exp. 14, 395–413 (1972).

  3. 3

    Vivalan Symposium J. intern. Med. Res. 3, suppl. 3 (1975).

  4. 4

    Gluckman, M. I. & Baum, T. Psychopharmacologia 15, 169–185 (1969).

  5. 5

    Van Riezen, H., Behagel, I. R. H. & Chafik, M. Psychopharmac. Bull. 11, 10–15 (1975).

  6. 6

    Greenwood, D. T. J. Intern. Med. Res. 3, suppl. 3, 18–30 (1975).

  7. 7

    Jalfre, M. & Haefely, W. in 6-Hydroxydopamine and Catecholamine Neurons (eds Malmfors, T. & Thoenen, H.) 333–346 (North-Holland, Amsterdam, 1971).

  8. 8

    Schildkraut, J. Am. J. Psychiat. 122, 509–522 (1965).

  9. 9

    Helmchen, H. & Hippius, H. Nervenarzt 38, 455–458 (1967).

  10. 10

    Prange, A. J. in The Nature and Treatment of Depression (eds Flach, F. F. & Draghi, S. C.) 255–270 (Wiley, New York, 1975).

  11. 11

    Van Riezen, H. Arch. Intern. Pharmacodyn. 198, 256–269 (1972).

  12. 12

    Kafoe, W. F. & Leonard, B. E. Arch. Intern. Pharmacodyn. 206, 389–391 (1973).

  13. 13

    Jalfre, M., Ruch-Monachon, M. A. & Haefely, W. Adv. Biochem. Psychopharmac. 10, 121–134 (1974).

  14. 14

    Fleischhauer, J., Al-Shaltchi, B. & Brândli, A. Arzneim. Forsch. 23, 1808–1813 (1973).

  15. 15

    Dunnett, C. W. J. Am. Stat. Assoc. 50, 1096–1121 (1955).

Download references

Author information

Author notes

    • R. D. PORSOLT
    •  & M. JALFRE

    Present address: Unité de Neuropharmacologie, Centre de Recherche Delalande, 10, rue des Carrières, 92500, Rueil-Malmaison, France

Affiliations

  1. Département de Neuropharmacologie, Synthélabo, SA, 58, rue de la Glacière, 75621, Paris, Cedex 13, France

    • R. D. PORSOLT
    • , M. LE PICHON
    •  & M. JALFRE

Authors

  1. Search for R. D. PORSOLT in:

  2. Search for M. LE PICHON in:

  3. Search for M. JALFRE in:

About this article

Publication history

Received

Accepted

Issue Date

DOI

https://doi.org/10.1038/266730a0

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.